Gene · 27329
Papers2,231
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
361 to 380 of 2,231
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| ANGPTL3 deficiency impairs lipoprotein production and produces adaptive changes in hepatic lipid metabolism. | J Lipid Res | 2024 | 38219820 | PubTator, text mining | PubMed |
| Unlocking the mysteries of VLDL: exploring its production, intracellular trafficking, and metabolism as therapeutic targets. | Lipids Health Dis | 2024 | 38216994 | PubTator, text mining | PubMed |
| ANGPTL4 accelerates ovarian serous cystadenocarcinoma carcinogenesis and angiogenesis in the tumor microenvironment by activating the JAK2/STAT3 pathway and interacting with ESM1. | J Transl Med | 2024 | 38212795 | PubTator, text mining | PubMed |
| Application of improved GalNAc conjugation in development of cost-effective siRNA therapies targeting cardiovascular diseases. | Mol Ther | 2024 | 38204163 | PubTator, text mining | PubMed |
| The translational potential of miR-26 in atherosclerosis and development of agents for its target genes ACC1/2, COL1A1, CPT1A, FBP1, DGAT2, and SMAD7. | Cardiovasc Diabetol | 2024 | 38195542 | PubTator, text mining | PubMed |
| CTCA in children with severe heterozygous familial hypercholesterolaemia: Screening for subclinical atherosclerosis. | Atheroscler Plus | 2024 | 38188455 | PubTator, text mining | PubMed |
| Antibodies to watch in 2024. | MAbs | 2024 | 38178784 | PubTator, text mining | PubMed |
| A novel fully human anti-NT-ANGPTL3 antibody from phage display library exhibits potent ApoB, TG, and LDL-C lowering activities in hyperlipidemia mice. | FASEB J | 2024 | 38174870 | PubTator, text mining | PubMed |
| Effects of exercise training on ANGPTL3/8 and ANGPTL4/8 and their associations with cardiometabolic traits. | J Lipid Res | 2024 | 38160757 | PubTator, text mining | PubMed |
| Hepatic fat changes with antisense oligonucleotide therapy targeting ANGPTL3. | J Clin Lipidol | 2024 | 38158248 | PubTator, text mining | PubMed |
| Modern approaches to the management of homozygous familial hypercholesterolemia in the Middle East and North Africa. | J Clin Lipidol | 2024 | 38158247 | PubTator, text mining | PubMed |
| The serum levels of angiopoietin-like protein 3 and 4 in type 2 diabetic patients with and without metabolic syndrome compared to the control group. | Endocrinol Diabetes Metab | 2024 | 38140923 | PubTator, text mining | PubMed |
| Angiopoietin-like protein 8: a multifaceted protein instrumental in regulating triglyceride metabolism. | Curr Opin Lipidol | 2024 | 37962908 | PubTator, text mining | PubMed |
| Association of Genotypes of ANGPTL3 with Vitamin D and Calcium Concentration in Cardiovascular Disease. | Biochem Genet | 2024 | 37955843 | PubTator, text mining | PubMed |
| Lipid-lowering in diabetes: An update. | Atherosclerosis | 2024 | 37945448 | PubTator, text mining | PubMed |
| Novel insights into causal effects of serum lipids and lipid-modifying targets on cholelithiasis. | Gut | 2024 | 37945330 | PubTator, text mining | PubMed |
| Assessing Long-Term Liver Safety of Statins and PCSK9 Inhibitors Using Human Genetics. | Cell Mol Gastroenterol Hepatol | 2024 | 37944904 | PubTator, text mining | PubMed |
| Evinacumab for Pediatric Patients With Homozygous Familial Hypercholesterolemia. | Circulation | 2024 | 37860863 | PubTator, text mining | PubMed |
| Residual cardiovascular risk: When should we treat it? | Eur J Intern Med | 2024 | 37845117 | PubTator, text mining | PubMed |
| Adaptive and maladaptive roles of different angiotensin receptors in the development of cardiac hypertrophy and heart failure. | Can J Physiol Pharmacol | 2024 | 37748204 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/27329/papers?page=19